Physician profile
Magi Labib
NPI 1467867986
$3,311.81
in general payments reported to CMS, 2019-2025
20 companies · $590 in 2025
The $590 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.09 · 2020: $113 · 2021: $706 · 2022: $720 · 2023: $900 · 2024: $187 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $586.21 | 2019-2024 | Cequa |
| Alcon Vision LLC | $401.22 | 2021-2025 | Clareon, Total30, Lensx |
| Allergan, INC. | $383.94 | 2021-2022 | |
| Abbvie INC. | $243.79 | 2022-2025 | |
| Biotissue Holdings INC. | $229.71 | 2021-2025 | |
| Oyster Point Pharma, INC. | $209.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $191.38 | 2020-2023 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $183.46 | 2022-2025 | Xiidra, Biotrue, Infuse |
| Tarsus Pharmaceuticals, INC. | $181.90 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $166.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $163.30 | 2020-2022 | |
| Lkc Technologies, INC. | $138.15 | 2025 | |
| Harrow Eye, LLC | $66.79 | 2025 | Vevye |
| Eyepoint US, INC. | $35.81 | 2021 | |
| Dompe US, INC. | $26.10 | 2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $25.36 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.19 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $20.13 | 2025 | |
| Celularity INC. | $17.90 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magi Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.